Nirmatrelvir and ritonavir

(Paxlovid®)

Paxlovid®

Drug updated on 11/15/2023

Dosage FormTablet (oral; 150 mg nirmatrelvir co-packaged with 100 mg ritonavir)
Drug ClassAntiviral combinations
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Product Monograph / Prescribing Information

Document TitleYearSource
Paxlovid (nirmatrelvir, ritonavir) Prescribing Information. 2023Pfizer Laboratories, Div Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies. 2023PLoS One
Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: A systematic review. 2023Reviews in Medical Virology
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: An updated meta-analysis and trial sequential analysis. 2023Reviews in Medical Virology
Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis. 2023Journal of Global Health
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis. 2023Journal of Medical Virology
Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.2023Journal of Medical Virology
Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis.2023Journal of Medical Virology
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. 2023Journal of Medical Virology
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. 2023Journal of Infection
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. 2022Cochrane Database of Systematic Reviews
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. 2022Annals of Medicine
The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.2022Viruses

Clinical Practice Guidelines